Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival

Background: Abiraterone Acetate (AA) is approved for the treatment of mCRPC after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated and for treatment of mCRPC progressed during or after docetaxel-based chemotherapy regimen. The aim of this study is to evalu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Facchini, Gaetano, Caffo, Orazio, Ortega, Cinzia, D'Aniello, Carmine, Di Napoli, Marilena, Cecere, Sabrina C., Della Pepa, Chiara, Crispo, Anna, Maines, Francesca, Ruatta, Fiorella, Iovane, Gelsomina, Pisconti, Salvatore, Montella, Maurizio, Berretta, Massimiliano, Pignata, Sandro, Cavaliere, Carla
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2016
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4870277/
https://ncbi.nlm.nih.gov/pubmed/27242530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00123
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados